Gemtuzumab Ozogamicin represents a novel step forward in the treatment of relapsed leukemic malignancy, especially relapsed leukemic disease (AML). This novel medication joins a monoclonal antibody directed at the https://www.targetmol.com/compound/gemtuzumab